Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis
© Abay; licensee BioMed Central Ltd. 2013
Received: 5 June 2013
Accepted: 20 September 2013
Published: 24 September 2013
Among the currently used drugs in malaria case management, artemisinin derivatives and primaquine have an impact on the transmissible stages of Plasmodium falciparum. Hence, they reduce the transmission of the parasite from the patient to the mosquitoes. The present study aimed to assess evidence for this hypothesis from controlled trials.
All controlled clinical trials evaluating the transmission blocking activity of artemisinin derivatives and primaquine with or without other antimalarials were included in this systematic review. PubMed, Google Scholar, Web of Science, ScienceDirect, Medscape and the Cochrane library were systematically searched without language, publication status or date restrictions. The literature references were also scanned manually. The last search was run on July 15, 2013. Search terms included artemisinin derivatives, primaquine, malaria transmission, transmission blocking/reducing drugs and mosquito infection. The outcome measure was the mosquito infectivity rate after treatment of patients. Data were compared using odds ratio (OR), in random effects models.
Nine trials with a total of 13,831 mosquitoes were included in the meta-analysis. After combining the trials, the transmission of P. falciparum to Anopheles mosquitoes were lower in artesunate, artemether-lumefantrine and primaquine groups as compared with their control counterparts with OR of 0.36 (95% confidence interval (CI), 0.14-0.90), 0.49 (95% CI, 0.31-0.79) and 0.09 (95% CI, 0.01-0.73); respectively. In non-comparative longitudinal studies, the use of a single-dose of primaquine was shown to deter the transmission of malaria briefly.
Evidence on the transmission blocking effect of artemisinin derivatives and primaquine is conclusive. Trials evaluating the combined impact of artemisinin derivatives and primaquine on malaria transmission is urgently needed.
KeywordsMalaria transmission blocking Artesunate Artemether-lumefantrine Primaquine Systematic review Meta-analysis
Globally, an estimated 3.3 billion people were at risk of malaria in 2011, with populations living in sub-Saharan Africa having the highest risk of malaria infection . Between 2000 and 2010, malaria mortality rates fell by 26% around the world. In the World Health Organization (WHO) African Region the decrease was 33%. During this period, an estimated 1.1 million malaria deaths were averted globally, primarily as a result of a scale-up of interventions with a proven track record [2, 3]. However, malaria transmission still occurs in 99 countries around the world, and the malaria burden continues to cripple health systems in many African countries. In 2010, this entirely preventable and treatable disease caused an estimated 655,000 deaths worldwide .
Proven strategies for malaria control include early treatment of the illness with artemisinin-based combination therapies (ACTs) , intermittent preventive treatment for pregnant women (IPTP) , and using measures that reduce the risk of infection such as indoor residual spraying (IRS) or insecticide-treated nets (ITNs) . These tools and strategies have shown to be effective at contributing to malaria control . Among the drugs used currently in malaria case management, the ACTs and primaquine have an impact on the transmissible stages of Plasmodium falciparum. It is assumed that artemisinin derivatives act against young gametocytes, whereas primaquine acts on mature gametocytes, which are usually present in the circulation at the time when the patient presents for treatment .
Independent reports and a pooled data analysis study speculated about the malaria transmission reduction by artemisinin derivatives from malaria patients to Anopheles gambiae, a major malaria vector in Africa . Similarly, many studies have reflected the impact of primaquine on malaria transmission from patients to Anopheles stephensi, a sub-tropical species that predominates in Asia. However, no systematic analysis has been performed on the transmission blocking activity of artemisinin derivatives and primaquine. The present study attempts to make a systematic review and meta-analysis of the impact of artemisinin derivatives and primaquine on malaria transmission to the vector, and to measure whether there are general trends across the different reports on the change in malaria transmission due to artemisinin derivatives and primaquine. The study also explores the reasons for variations across the reports.
Conduct of systematic review and search strategy
Inclusion and exclusion criteria
Once it was determined that a paper contained a study on malaria transmission after interventions (artemisinin derivatives or primaquine), the full length article was consulted to check whether studies fulfill the following inclusion criteria for the meta-analysis:
i. controlled clinical trial on malaria patients;
ii. study on malaria transmission test from a patient to mosquito after treating the patient with the existing antimalarials; and
iii. evaluating mosquito mid-gut for oocyst prevalence to measure the extent of malaria transmission.
Similar trials with the aforementioned criteria were also included for the qualitative synthesis. Studies involving laboratory animals or trials without control arms were excluded in the meta-analysis.
Study design and outcome measures
The endpoints were mosquito infection prevalence out of all mosquitoes getting a blood-meal on patients after treatment with antimalarials. The endpoint evaluation was done in mosquitoes following their blood-meal directly on patients and artificial membrane feeding apparatus in primaquine trials and artemisinin derivatives; respectively. A data extraction sheet was used by the investigator to calculate the prevalence of mosquito infection in each trial. Information was extracted from each included trial on characteristics of trial participants, types of intervention (including type, dose, duration and frequency) and trial outcomes (mosquito infection prevalence). The odds of the end points from mosquitoes in the categories of artemisinin derivatives/primaquine and control (standard drugs) were calculated. The odds ratio (OR) and 95% confidence intervals (CI) for the prevalence of mosquito infection was then calculated.
The risk of bias in the studies used for meta-analysis was assessed by the investigator in an un-blinded manner using a tool developed by the Cochrane Collaboration (focusing on specific domains including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting) . Due to the small number of studies identified, trials were not excluded based on quality assessment. For the same reason, publication bias was not assessed .
Meta-analysis was performed using Meta-analyst, a software for meta-analysis of binary, continuous and diagnostic data . The random effect method was used to test for differences in binary outcomes between artemisinin derivatives/primaquine and control (standard drug).
Heterogeneity, the variations among study outcomes, was checked by tau2 statistic, chi-square based Q-test, I 2 statistics and heterogeneity P-value. The author chose the random effects meta-analytic model (DerSimonian and Laird)  to calculate the combined OR and 95% CI, even in a meta-analysis with low level of heterogeneity, in order to accommodate the random variation within the studies and the variation between the different studies.
Description of included studies
Characteristics of trials included in the meta-analysis
Mosquitoes (numbers used)
Mosquito infection method
Children (1–9 yrs)
Artesunate [a] + chloroquine [b]; chloroquine [b]
Anopheles gambiae (1208)
Artesunate [a] + sulfadoxine-pyrimethamine [f]; sulfadoxine-pyrimethamine [f]
Anopheles gambiae (3192)
Artesuante [g] + sulfadoxine-pyrimethamine [f]; sulfadoxine-pyrimethamine [f]
Anopheles gambiae (2688)
Children (6 months–10 yrs)
Sulfadoxine-pyrimethamine [h] + placebo [i]; artesunate [a] + sulfadoxine-pyrimethamine [h]; sulfadoxine-pyrimethamine [h] + Amodiaquine [j]; artemether-lumefantrine [k]
Anopheles gambiae (3000)
Children (1-10 yrs)
Artemether-lumefantrine [c]; chloroquine[d] + sulfadoxine-pyrimethamine [e]
Anopheles gambiae (540)
Primaquine [l]; Sulfadiazine + pyrimethamine [m]
Anopheles stephensi (30)
Direct skin bite
Adults (25 to 41 yrs)
Primaquine [l]; pyrimethamine [n]
Anopheles stephensi (163)
Direct skin bite
Some of the publications, which fulfilled the inclusion criteria, had results of multiple studies; and these were used to generate effect sizes for the transmission blocking property of drugs (artesunate, artemether or primaquine) vs. controls. The studies used in the quantitative analysis were from Africa (Gambia and Kenya) and USA dealing with artemisinin derivatives and primaquine; respectively.
Study quality assessment
Risk of bias assessment within the trials
Study location (year)
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants & personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Statistics to test heterogeneity in the meta-analysis
Model used for meta-analysis*
With artesunate vs. without artesunate
79.7 (df = 5)
Artemether-lumefantrine vs. other antimalarials
2.77 (df = 2)
Primaquine vs. other antimalarial
5.15 (df = 3)
Artesunate-based combinations versus antimalarials without artesunate
Artemether-lumefantrine versus other antimalarials
The meta-analysis was in favour of artemisinin derivatives in reducing malaria transmission (Figures 2 and 3). In two randomised trials, the transmission blocking activity of ACTs were compared. In the first study, treatment with artemether-lumefantrine was associated with a lower proportion of infected mosquitoes as compared with dihyroartemisinin-piperaquine (OR 0.53; 95% CI, 0.37- 0.77) . The second study comparing artemether-lumefantrine and artesunate in combination with sulfadoxine-pyrimethamine did not show any difference in the proportion of infected mosquitoes (OR 1.60; 95% CI, 0.87-2.98) .
Primaquine single dose versus other antimalarials
Single-dose of primaquine and malaria transmission at different points in time
In more than 93% of all the patients, the Plasmodium transmission to the mosquitoes had been blocked within the third day of administration of a single dose of primaquine. However, mosquitoes feeding on patients after 10 days of treatment became oocyst-positive. Briefly, this has been revealed in a study that followed patients for two weeks. Mosquitoes, fed on one patient on the 14th day and a second patient on the 11th and 15th days after primaquine treatment, became oocyst-positive (Figure 5).
Addition of primaquine to antimalarials and malaria transmission: the mefloquine case
In the mefloquine plus primaquine group, the transmission of malaria was blocked throughout the duration of follow-up, i.e. 3 weeks (Figure 6). This duration of transmission blockade was longer than the duration (about 10 days) reported in those studies, which used only primaquine (Figure 5).
Preventing mosquitoes from biting by the existing tools (e.g. ITNs and IRS) and blocking the transmission of Plasmodium parasites from patients to mosquitoes using agents (vaccine or drugs) may substantially improve public health through reducing the burden of malaria . In areas of stable malaria, a meta-analysis of ITNs on malaria transmission revealed a reduction by 50% . However, a meta-analysis on existing antimalarials to block the transmission of the parasite from patients to mosquitoes has not yet been done to the author’s knowledge.
The current meta-analysis re-affirmed the advantage of ACTs in reducing transmission of Plasmodium to the mosquitoes. In the overall analysis, the odds of transmission of malaria in artesunate-based combination treatment group was 2.78 times less than the odds of transmission of malaria in antimalarials without artesunate (Figure 2). Similarly, the odds of malaria transmission to mosquitoes in artemether-lumefantrine treated group was 2 times less than the odds on other antimalarials used in the studies (Figure 3). Exceptionally, in one trial , the odds of parasite transmission was higher in artesunate-based combination therapy than the standard therapy without artesunate. This difference might be attributed to the use of only one dose of artesunate in the trial.
From the current analysis of the published articles, artesunate- and artemether-based therapy could reduce the transmission of the parasite to the mosquitoes. Thus, these medications, in addition to their role in the clinical case management of malaria, can have an impact on the overall transmission rate of malaria and play a role in controlling malaria.
Primaquine, the old antimalarial drug mainly used in terminal cure of P. vivax infection, was also tested for its impact on the transmission of Plasmodium to mosquitoes. Trials compared the transmission blocking effect of single-dose primaquine with the conventional antimalarials: sulfadoxine-pyrimethamine and pyrimethamine. The current analysis showed that odds of mosquito infection rate was 11 times less for single-dose primaquine relative to the comparative medicine (Figure 4).
In non-comparative longitudinal trials of single-dose primaquine, the current systematic review presented the trends of mosquito infection rate across successive post-treatment days (Figure 5). There was a rapid drop in mosquito infection rate as illustrated in those mosquitoes feeding on the first and second days post-treatment. However, the effect was maintained only for a short period as evidenced by the positivity of mosquitoes biting on some patients after the 10 days of single-dose primaquine therapy. As the trials employed single-dose primaquine therapy, which might target only the mature gametocyte , the continuity of transmission blockade by a single dose of primaquine fails against the new wave of mature gametocytes that appear after primaquine has been washed out .
The use of single-dose primaquine blocks the transmission of malaria temporarily (Figure 5). However, combining it with effective antimalarials - like mefloquine used in the trial conducted by Chen and his colleague - results in a disruption of Plasmodium transmission to the vector for a longer period (Figure 6). This might be explained by the fact that the effective schizonticide (mefloquine), by clearing the parasite, dries out the potential source for a new wave of gametocytes.
Following the introduction of ACTs in malaria case management, many researchers report the additional benefit of ACTs on the partial gametocytocidal effect compared with the non-ACTs regimens [30–34]. Recently, there is also interest of combining ACTs with single-dose primaquine, particularly in areas with a resistant Plasmodium to ACTs or in the phase of malaria elimination. The addition of primaquine to ACTs results in a further reduction in gametocyte carriage rate that can have implications on the extent of malaria transmission [35–39]. However, the optimal time of administration, treatment duration and dose of primaquine needs to be understood for improved outcomes. Further studies are also required to understand the transmission blocking effect upon the addition of primaquine to ACT regimens at the mosquito level, which is a gold standard approach to evaluate malaria transmission.
The present paper analysed the transmission blocking activity of artemisinin derivatives and primaquine. The clinical trials of artemisinin derivatives and primaquine focused on An. gambiae and An. stephensi; respectively. None of the identified literatures pertained to other dominant malaria vectors such as An. funestus and An. arabiensis[40–42]. In all of the trials included for meta-analysis, similar colonies of mosquitoes in both intervention and control groups were used. By so doing, confounding bias related to the variable infection success in the different species of vectors could be avoided. Of course, if the variability in susceptibility of the vectors to P. falciparum infection modified the transmission blocking activity of drugs, trials with different species of malaria vectors having a range of infection success would be required; then systematic reviews should consider subgroup analysis.
Like any retrospective study, this systematic review has a number of limitations. The literature search might have missed some trials. The author assumed that missing reports is unlikely for two reasons. Firstly, a proper search strategy was followed to identify literatures. Secondly, the research groups working on transmission blocking trials at the level of mosquitoes are few. Another concern is the comparison of the reference drugs (artemisinin derivatives and primaquine) with a heterogeneous array of antimalarials probably with different gametocytocidal activity, which in turn might obscure some systematic differences between drugs. To minimize these risk, random analytic method was followed in all data analysis, including in those with little heterogeneity.
Based on the data reviewed, artemisinin derivatives (artesunate and artemether) and primaquine reduce the transmission of P. falciparum from the patient to the mosquitoes. Combining the two medications, after a proper optimization study, might further reduce the transmission of malaria.
SMA conceived the idea and designed the study, made both qualitative and quantitative synthesis of reported trials, wrote and revised the manuscript.
The author thanks Giancarlo Nardini, a librarian at University of Camerino, for the provision of essential articles. The author is also very grateful to anonymous reviewers for their meticulous reading of the paper.
- World Health Organization: Global Health Observatory. [http://www.who.int/gho/malaria/en]
- World Health Organization: Malaria- factsheet on the world malaria report. 2012, [http://www.who.int/malaria/media/world_malaria_report_2012_facts/en/]
- Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD: Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012, 379: 413-31.View ArticlePubMed
- World Health Organization: Media center- World malaria day. [http://www.who.int/mediacentre/news/releases/2012/malaria_20120424/en/]
- Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996, 347: 1654-8.View ArticlePubMed
- World Health Organization: WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). [http://www.who.int/malaria/publications/atoz/Policy_brief_IPTp-SP_implementation_11april2013.pdf.pdf]
- Okumu FO, Moore SJ: Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future. Malar J. 2011, 10: 208-PubMed CentralView ArticlePubMed
- Centers for Disease Control and Prevention: Malaria: Current and Future Research. [http://www.cdc.gov/malaria/tools_for_tomorrow/research_areas.html]
- Wilairatana P, Krudsood S, Tangpukdee N: Appropriate time for primaquine treatment to reduce Plasmodium falciparum transmission in hypoendemic areas. Korean J Parasitol. 2010, 48: 179-182.PubMed CentralView ArticlePubMed
- Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ: Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J. 2008, 7: 125-PubMed CentralView ArticlePubMed
- Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009, 6: e1000097-View Article
- Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [http://www.cochrane-handbook.org]
- Wallace BC, Schmid CH, Lau J, Trikalinos TA: Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009, 9: 80-PubMed CentralView ArticlePubMed
- DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188.View ArticlePubMed
- Drakeley CJ, Jawara M, Targett GAT, Walraven G, Obisike U, Coleman R, Pinder M, Sutherland CJ: Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health. 2004, 9: 53-61.View ArticlePubMed
- Targett G, Drakeley C, Jawara M, Seiden L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, Milligan P: Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001, 183: 1254-9.View ArticlePubMed
- Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW: Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006, 193: 1151-9.View ArticlePubMed
- Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GAT: Reduction of malaria transmission to Anopheles mosquitoes with a six-dose of regimen o Co-artemether. PLoS Med. 2005, 2: e92-PubMed CentralView ArticlePubMed
- Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD:Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain ofPlasmodium falciparum. Bull World Health Organ. 1968, 38: 625-32.PubMed CentralPubMed
- Clyde DK, Miller RM, Music SI, McCarthy VC: Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Vietnam. Am J Trop Med Hyg. 1971, 20: 1-5.PubMed
- Schrol JB, Moustgaard R, Gøtzsche PC: Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011, 11: 22-View Article
- Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, Manjurano A, Kavishe RA, Beshir KB, Yussuf RU, Omar SA, Hermsen CC, Okell L, Schallig HD, Sauerwein RW, Hallett RL, Bousema T: Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis. 2013, 207: 1637-45.View ArticlePubMed
- Clyde DK, DuPont HI, Miller RM, McCarthy VC: Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Malaya. Trans R Soc Trop Med Hyg. 1970, 64: 834-838.View ArticlePubMed
- Burgess RW, Bray RS: The Effect of a Single Dose of Primaquine on the Gametocytes, Garnetogony and Sporogony of Laverania falciparum. Bull World Health Organ. 1961, 24: 451-6.PubMed CentralPubMed
- Young MD: The effect of small doses of primaquine upon malaria infections. Indian J Malariol. 1959, 13: 69-72.
- Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ: The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J. 1994, 107: 709-11.PubMed
- Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez MG, Ghani AC: Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010, 7: e1000324-PubMed CentralView ArticlePubMed
- Lengeler C: Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev. 2004, 2: CD000363
- Fletcher KA, Evans DAP, Gilies HM, Greaves J, Bunnag D, Harinasuta T: Studies on the pharmacokinetics of primaquine. Bull World Health Organ. 1981, 59: 407-12.PubMed CentralPubMed
- Carmona-Fonseca J, Arango E, Blair S: Gametocytemia in falciparum malaria treated with amodiaquine or artesunate. Biomedica. 2008, 28: 195-212.View ArticlePubMed
- Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Odey FA, Oguche S, Ezeiru VI, Aina OO: Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria. Malar J. 2008, 7: 172-PubMed CentralView ArticlePubMed
- Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, Cohuet S, D’Alessandro U, Djimdé A, Karema C, Guthmann JP, Hamour S, Ndiaye JL, Mårtensson A, Rwagacondo C, Sagara I, Same-Ekobo A, Sirima SB, van den Broek I, Yeka A, Taylor WR, Dorsey G, Randrianarivelojosia M: Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009, 8: 203-PubMed CentralView ArticlePubMed
- Sowunmi A, Nkogho OO, Okuboyejo TM, Gbotosho GO, Happi CT, Adewoye EO: Effects of mefloquine and artesunate mefloquine on the emergence, clearance and sex ratio of Plasmodium falciparum gametocytes in malarious children. Malar J. 2009, 8: 297-PubMed CentralView ArticlePubMed
- Osorio L, Gonzalez I, Olliaro P, Taylor WR: Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia. Malar J. 2007, 6: 25-PubMed CentralView ArticlePubMed
- Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ: Activities of artesunate primaquine against asexual and sexual stages parasites in falciparum malaria. Antimicrob Agents Chemother. 2004, 48: 1329-34.PubMed CentralView ArticlePubMed
- Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ: Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010, 10: 673-81.PubMed CentralView ArticlePubMed
- Eliana M, Yulieth A, Carmona-Fonseca J: Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Trop. 2012, 122: 177-82.View Article
- Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Syafruddin D, Kusriastuti R, Hawley WA, Lobo NF, Ter Kuile FO: The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South Sumatra, Western Indonesia: an open-label, randomized, controlled trial. Clin Infect Dis. 2013, 56: 685-93.View ArticlePubMed
- Shah NK, Schapira A, Juliano JJ, Srivastava B, Macdonald PD, Poole C, Anvikar A, Meshnick SR, Valecha N, Mishra N: A non-randomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing the post-treatment circulation of Plasmodium falciparum gametocytes. Antimicrob Agents Chemother. 2013, 57: 2948-54.PubMed CentralView ArticlePubMed
- Mwangangi JM, Muturi EJ, Muriu SM, Nzovu J, Midega JT, Mbogo C: The role of Anopheles arabiensis and Anopheles coustani in indoor and outdoor malaria transmission in Taveta District, Kenya. Parasit Vectors. 2013, 6: 114-PubMed CentralView ArticlePubMed
- Lwetoijera DW, Kiware SS, Mageni ZD, Dongus S, Harris C, Devine GJ, Majambere S: A need for better housing to further reduce indoor malaria transmission in areas with high bed net coverage. Parasit Vectors. 2013, 6: 57-PubMed CentralView ArticlePubMed
- Tchouassi DP, Quakyi IA, Addison EA, Bosompem KM, Wilson MD, Appawu MA, Brown CA, Boakye DA: Characterization of malaria transmission by vector populations for improved interventions during the dry season in the Kpone-on-Sea area of coastal Ghana. Parasit Vectors. 2012, 5: 212-PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.